Huperzine A ameliorates experimental autoimmune encephalomyelitis via the suppression of T cell-mediated neuronal inflammation in mice

Experimental Neurology

Volumn 236, Issue 1, 2012, Pages 79-87

  Wang, Jun ^a   Chen, Fu ^a   Zheng, Peng ^a   Deng, Weijuan ^a   Yuan, Jia ^a   Peng, Bo ^a   Wang, Ruochen ^a   Liu, Wenjun ^a   Zhao, Hui ^a   Wang, Yanqing ^a   Wu, Gencheng ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Demyelination; Experimental autoimmune encephalomyelitis; Huperzine A; Inflammation; Multiple sclerosis; Spinal cord

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; HUPERZINE A; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; MECAMYLAMINE; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TWEAK PROTEIN; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AXONAL INJURY; CELL CULTURE; CELL METABOLISM; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; DEMYELINATION; DISEASE SEVERITY; DOWN REGULATION; DRUG INHIBITION; DRUG MECHANISM; FEMALE; IMMUNOMODULATION; INFLAMMATORY CELL; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SPINAL CORD; SPLEEN CELL; T LYMPHOCYTE;

ALKALOIDS; ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED C57BL; MYELITIS; NEUROPROTECTIVE AGENTS; PRIMARY CELL CULTURE; SESQUITERPENES; T-LYMPHOCYTES;

EID: 84861669839     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.03.024     Document Type: Article

References (42)

1. Alvarez J.I., Cayrol R., Prat A. Disruption of central nervous system barriers in multiple sclerosis. Biochim. Biophys. Acta 2011, 1812:252-264.
2. Bai D.L., Tang X.C., He X.C. Huperzine A, a potential therapeutic agent for treatment of Alzheimer's disease. Curr. Med. Chem. 2000, 7:355-374.
3. Barner E.L., Gray S.L. Donepezil use in Alzheimer disease. Ann. Pharmacother. 1998, 32:70-77.
4. Brini E., Ruffini F., Bergami A., Brambilla E., Dati G., Greco B., Cirillo R., Proudfoot A.E., Comi G., Furlan R., Zaratin P., Martino G. Administration of a monomeric CCL2 variant to EAE mice inhibits inflammatory cell recruitment and protects from demyelination and axonal loss. J. Neuroimmunol. 2009, 209:33-39.
5. Coleman B.R., Ratcliffe R.H., Oguntayo S.A., Shi X., Doctor B.P., Gordon R.K., Nambiar M.P. [+]-Huperzine A treatment protects against N-methyl-d-aspartate-induced seizure/status epilepticus in rats. Chem. Biol. Interact. 2008, 175:387-395.
6. Compston A., Coles A. Multiple sclerosis. Lancet 2008, 372:1502-1517.
7. Constantinescu C.S., Farooqi N., O'Brien K., Gran B. Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS). Br. J. Pharmacol. 2011, 164:1079-1106.
8. Dalcanto M.C., Wisniewski H.M., Johnson A.B., Brostoff S.W., Raine C.S. Vesicular disruption of myelin in autoimmune demyelination. J. Neurol. Sci. 1975, 24:313-319.
9. Desilets A.R., Gickas J.J., Dunican K.C. Role of huperzine a in the treatment of Alzheimer's disease. Ann. Pharmacother. 2009, 43:514-518.
10. Eggert M., Goertsches R., Seeck U., Dilk S., Neeck G., Zettl U.K. Changes in the activation level of NF-kappa B in lymphocytes of MS patients during glucocorticoid pulse therapy. J. Neurol. Sci. 2008, 264:145-150.
11. El-behi M., Rostami A., Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J. Neuroimmune Pharmacol. 2010, 5:189-197.
12. Ezoulin M.J., Liu Z., Dutertre-Catella H., Wu G., Dong C.Z., Heymans F., Ombetta J.E., Rat P., Massicot F. A new acetylcholinesterase inhibitor with anti-PAF activity modulates oxidative stress and pro-inflammatory mediators release in stimulated RAW 264.7 macrophage cells. Comparison with tacrine. Int. Immunopharmacol. 2007, 7:1685-1694.
13. Fagone P., Mangano K., Quattrocchi C., Motterlini R., Di Marco R., Magro G., Penacho N., Romao C.C., Nicoletti F. Prevention of clinical and histological signs of proteolipid protein (PLP)-induced experimental allergic encephalomyelitis (EAE) in mice by the water-soluble carbon monoxide-releasing molecule (CORM)-A1. Clin. Exp. Immunol. 2011, 163:368-374.
14. Fu L.M., Li J.T. A systematic review of single Chinese herbs for Alzheimer's disease treatment. Evid. Based Complement. Altern. Med. 2009, 10.1093/ecam/nep1136.
15. Glass W.G., Hickey M.J., Hardison J.L., Liu M.T., Manning J.E., Lane T.E. Antibody targeting of the CC chemokine ligand 5 results in diminished leukocyte infiltration into the central nervous system and reduced neurologic disease in a viral model of multiple sclerosis. J. Immunol. 2004, 172:4018-4025.
16. Ha G.T., Wong R.K., Zhang Y. Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies. Chem. Biodivers. 2011, 8:1189-1204.
17. Hao J., Simard A.R., Turner G.H., Wu J., Whiteaker P., Lukas R.J., Shi F.D. Attenuation of CNS inflammatory responses by nicotine involves alpha7 and non-alpha7 nicotinic receptors. Exp. Neurol. 2011, 227:110-119.
18. Harrington L.E., Hatton R.D., Mangan P.R., Turner H., Murphy T.L., Murphy K.M., Weaver C.T. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 2005, 6:1123-1132.
19. Hart B.A., Gran B., Weissert R. EAE: imperfect but useful models of multiple sclerosis. Trends Mol. Med. 2011, 17:119-125.
20. Hemendinger R.A., Armstrong E.J., Persinski R., Todd J., Mougeot J.L., Volvovitz F., Rosenfeld J. Huperzine A provides neuroprotection against several cell death inducers using in vitro model systems of motor neuron cell death. Neurotox. Res. 2008, 13:49-61.
21. Langrish C.L., Chen Y., Blumenschein W.M., Mattson J., Basham B., Sedgwick J.D., McClanahan T., Kastelein R.A., Cua D.J. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 2005, 201:233-240.
22. Maggi L., Mantegazza R. Treatment of myasthenia gravis: focus on pyridostigmine. Clin. Drug Invest. 2011, 31:691-701.
23. Mahad D., Callahan M.K., Williams K.A., Ubogu E.E., Kivisakk P., Tucky B., Kidd G., Kingsbury G.A., Chang A., Fox R.J., Mack M., Sniderman M.B., Ravid R., Staugaitis S.M., Stins M.F., Ransohoff R.M. Modulating CCR2 and CCL2 at the blood-brain barrier: relevance for multiple sclerosis pathogenesis. Brain 2006, 129:212-223.
24. Nizri E., Hamra-Amitay Y., Sicsic C., Lavon I., Brenner T. Anti-inflammatory properties of cholinergic up-regulation: a new role for acetylcholinesterase inhibitors. Neuropharmacology 2006, 50:540-547.
25. Nizri E., Irony-Tur-Sinai M., Faranesh N., Lavon I., Lavi E., Weinstock M., Brenner T. Suppression of neuroinflammation and immunomodulation by the acetylcholinesterase inhibitor rivastigmine. J. Neuroimmunol. 2008, 203:12-22.
26. Pavlov V.A., Parrish W.R., Rosas-Ballina M., Ochani M., Puerta M., Ochani K., Chavan S., Al-Abed Y., Tracey K.J. Brain acetylcholinesterase activity controls systemic cytokine levels through the cholinergic anti-inflammatory pathway. Brain Behav. Immun. 2009, 23:41-45.
27. Reale M., Iarlori C., Gambi F., Lucci I., Salvatore M., Gambi D. Acetylcholinesterase inhibitors effects on oncostatin-M, interleukin-1 beta and interleukin-6 release from lymphocytes of Alzheimer's disease patients. Exp. Gerontol. 2005, 40:165-171.
28. Reale M., Iarlori C., Gambi F., Feliciani C., Isabella L., Gambi D. The acetylcholinesterase inhibitor, Donepezil, regulates a Th2 bias in Alzheimer's disease patients. Neuropharmacology 2006, 50:606-613.
29. Reale M., Iarlori C., Feliciani C., Gambi D. Peripheral chemokine receptors, their ligands, cytokines and Alzheimer's disease. J. Alzheimers Dis. 2008, 14:147-159.
30. Schneider B.M., Dodman N.H., Faissler D., Ogata N. Clinical use of an herbal-derived compound (Huperzine A) to treat putative complex partial seizures in a dog. Epilepsy Behav. 2009, 15:529-534.
31. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
32. Tracey K.J. Physiology and immunology of the cholinergic antiinflammatory pathway. J. Clin. Invest. 2007, 117:289-296.
33. Wang Y.E., Yue D.X., Tang X.C. Anti-cholinesterase activity of huperzine A. Zhongguo Yao Li Xue Bao 1986, 7:110-113.
34. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., Li J.H., Wang H., Yang H., Ulloa L., Al-Abed Y., Czura C.J., Tracey K.J. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388.
35. Wang R., Yan H., Tang X.C. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol. Sin. 2006, 27:1-26.
36. Wang Z.F., Tang L.L., Yan H., Wang Y.J., Tang X.C. Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. Pharmacol. Biochem. Behav. 2006, 83:603-611.
37. Wang Z.F., Wang J., Zhang H.Y., Tang X.C. Huperzine A exhibits anti-inflammatory and neuroprotective effects in a rat model of transient focal cerebral ischemia. J. Neurochem. 2008, 106:1594-1603.
38. Wang B.S., Wang H., Wei Z.H., Song Y.Y., Zhang L., Chen H.Z. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis. J. Neural Transm. 2009, 116:457-465.
39. Wang J., Zhang H.Y., Tang X.C. Huperzine a improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion. J. Neurosci. Res. 2010, 88:807-815.
40. Wilson E.H., Weninger W., Hunter C.A. Trafficking of immune cells in the central nervous system. J. Clin. Invest. 2010, 120:1368-1379.
41. Zangara A. The psychopharmacology of huperzine A: an alkaloid with cognitive enhancing and neuroprotective properties of interest in the treatment of Alzheimer's disease. Pharmacol. Biochem. Behav. 2003, 75:675-686.
42. Zhou J., Tang X.C. Huperzine A attenuates apoptosis and mitochondria-dependent caspase-3 in rat cortical neurons. FEBS Lett. 2002, 526:21-25.